The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ACCELERON PHARMA INC COM 00434H108 344,200 2,000,000 SH   SOLE   2,000,000 0 0
ACLARIS THERAPEUTICS INC COM 00461U105 2,869 159,393 SH   SOLE   159,393 0 0
ADAGIO THERAPEUTICS INC COM 00534A102 3,655 86,528 SH   SOLE   86,528 0 0
AEROVATE THERAPEUTICS INC COM 008064107 262 12,484 SH   SOLE   12,484 0 0
BIONTECH SE SPONSORED ADS 09075V102 36,289 132,932 SH   SOLE   132,932 0 0
BRIDGEBIO PHARMA INC COM 10806X102 11,891 253,692 SH   SOLE   253,692 0 0
FATE THERAPEUTICS INC COM 31189P102 20,937 353,250 SH   SOLE   353,250 0 0
FULCRUM THERAPEUTICS INC COM 359616109 959 33,997 SH   SOLE   33,997 0 0
INHIBRX INC COM 45720L107 18,074 542,586 SH   SOLE   542,586 0 0
INTELLIA THERAPEUTICS INC COM 45826J105 100,884 752,024 SH   SOLE   752,024 0 0
VERVE THERAPEUTICS INC COM 92539P101 1,288 27,397 SH   SOLE   27,397 0 0
VIR BIOTECHNOLOGY INC COM 92764N102 1,972 45,311 SH   SOLE   45,311 0 0